Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989.
A total of 3303 healthy children and adolescents, aged 12 months to 17 years, were vaccinated with one of five production lots of a live attenuated varicella vaccine (VARIVAX) containing 1000 to 1625 plaque-forming units per dose. The vaccine was generally well tolerated. Ninety-six percent (2381/2475) of vaccinees responded to vaccination by producing antibody as measured by a glycoprotein-based enzyme-linked immunosorbent assay; 99% (569/576) of those tested maintained antibody at 1 year following vaccination. The incidence of varicella following household exposure in vaccinees was approximately 12%; household contact historically results in 87% infection. Nearly all of the vaccinees who had varicella after vaccination had a clinically modified disease.
White
C J
CJ
Department of Clinical Research, Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania 19486.
Kuter
B J
BJ
Hildebrand
C S
CS
Isganitis
K L
KL
Matthews
H
H
Miller
W J
WJ
Provost
P J
PJ
Ellis
R W
RW
Gerety
R J
RJ
Calandra
G B
GB
D000293:Adolescent; D000914:Antibodies, Viral / Q000097:blood*; D002644:Chickenpox / Q000517:prevention & control*; D019433:Chickenpox Vaccine; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D005260:Female; D014645:Herpesvirus 3, Human / Q000276:immunology*; D006801:Humans; D007223:Infant; D008297:Male; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology
D000914:Antibodies, Viral; D019433:Chickenpox Vaccine; D014765:Viral Vaccines